Shionogi & Co Ltd (SGIOF) Q3 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

This is Kyokawa of the Corporate Communication Department of Shionogi. Thank you very much for gathering today. From now, we would like to begin the presentation of the third quarter of fiscal 2024 financial results from Shionogi and Company Limited. First of all, let me introduce the people who are here with us. First of all, Toshinobu Iwasaki, Senior Executive Officer, Healthcare Business Supervisory Unit. Next, Koji Hanasaki, Senior Executive Officer of Supply Supervisory Unit. Next is Kazuhiro Hatanaka, Senior Executive Officer, Corporate Supervisory Unit and Corporate Strategy Division. And next is Takeki Uehara, Corporate Officer of Drug Development and Regulatory Science Division. Uehara-san is joining from different venue online. And we have Masako Kudo from the Finance and Accounting Department. Let me briefly explain the flow of today's meeting. First of all, we would like to give you the overview of the Q3 FY2024 financial results and transformation of Chinese business and pipeline progress will be explained, and we will have Q&A session after that. We will have a simultaneous interpretation service for this meeting, so if you are going to use the translation, Please press the globe icon and select the language you wish to listen to. Now let us begin. Ms. Kudo, please. Yes, I would like to give you the overview of the Q3 FY2024 financial results. First, on page 4, this is the highlight of financial results. Sales revenue was 333.6 billion yen, down 3.2 billion yen from last year's 336.8 billion yen. However, excluding the one-time payment of 25 billion yen associated with the license transfer of an ADHD drug that was recorded in the first quarter of last year, revenue increased by 21.8 billion yen, due to the significant growth of royalty income and overse...